The Sidney Kimmel Cancer Center at Thomas Jefferson University has been developing a scalable telehealth program long before the spread of SARS-CoV-2 in the United States.
Hollander: Fix telehealth infrastructure—or America will be just as unprepared for the next pandemic
As U.S. health systems switch to telehealth to connect with patients—via phone calls and online video conferencing—during the COVID-19 pandemic, providers are quickly learning that the lack of a national infrastructure for telehealth is making it difficult to reach patients.
A class of drugs that has been used to treat adverse events associated with CAR T-cell therapy is emerging as a potential treatment for COVID-19.
The China National Medical Products Administration accepted a supplemental New Drug Application for Zejula (niraparib) as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
England's National Institute for Health and Care Excellence has rejected Keytruda (pembrolizumab) in patients who receive locally advanced or metastatic urothelial carcinoma who have had platinum-containing chemotherapy.
FDA has approved Herzuma (trastuzumab-pkrb) for injection in the same indications as the biosimilar Herceptin.
Ideaya Biosciences Inc. and Pfizer Inc. have formed a clinical trial collaboration and supply agreement.
A study conducted by researchers at MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor activity in patients with four types of advanced, hard-to-treat rare cancers. Study findings were published in the March 17 online issue of the Journal for ImmunoTherapy of Cancer.
A combination of body mass index and levels of albumin, a protein made by the liver, can predict how well older adults with cancer will be able to tolerate the side effects of chemotherapy, according to a study led by a researcher at Fox Chase Cancer Center.
Advances in treatment have led to the largest yearly declines in deaths due to melanoma ever recorded for this skin cancer, results of a study suggest.
